Dimensional Fund Advisors
ATRA icon

Dimensional Fund Advisors’s Atara Biotherapeutics ATRA Stock Holding History

Dimensional Fund Advisors’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,028
Closed -$181K – 3219
2025
Q4 		$181K Buy
+10,028
New +$150K ﹤0.01% 3099
2023
Q4 		– Sell
-8,778
Closed -$325K – 3417
2023
Q3 		$325K Sell
8,778
-17,453
-67% -$777K ﹤0.01% 3125
2023
Q2 		$1.06M Sell
26,231
-31,055
-54% -$1.76M ﹤0.01% 2916
2023
Q1 		$4.15M Buy
57,286
+21,759
+61% +$2.11M ﹤0.01% 2534
2022
Q4 		$2.91K Buy
35,527
+10,848
+44% +$1.13M ﹤0.01% 2611
2022
Q3 		$2.33M Sell
24,679
-21,119
-46% -$2.37M ﹤0.01% 2670
2022
Q2 		$8.92M Sell
45,798
-7,812
-15% -$1.28M ﹤0.01% 2243
2022
Q1 		$12.5M Buy
53,610
+4,630
+9% +$1.47M ﹤0.01% 2197
2021
Q4 		$19.3M Buy
48,980
+12,543
+34% +$5.28M 0.01% 2010
2021
Q3 		$16.3M Sell
36,437
-17,193
-32% -$6.16M 0.01% 2102
2021
Q2 		$20.8M Buy
53,630
+4,988
+10% +$1.78M 0.01% 2030
2021
Q1 		$17.5M Buy
48,642
+12,428
+34% +$5.49M 0.01% 2080
2020
Q4 		$17.8M Buy
36,214
+2,939
+9% +$1.36M 0.01% 2038
2020
Q3 		$10.8M Buy
33,275
+1,060
+3% +$361K ﹤0.01% 2155
2020
Q2 		$11.7M Buy
32,215
+3,440
+12% +$869K 0.01% 2136
2020
Q1 		$6.12M Buy
28,775
+3,729
+15% +$1.18M ﹤0.01% 2327
2019
Q4 		$10.3M Buy
25,046
+3,052
+14% +$1.05M ﹤0.01% 2339
2019
Q3 		$7.76M Buy
21,994
+3,088
+16% +$1.15M ﹤0.01% 2449
2019
Q2 		$9.51M Sell
18,906
-196
-1% -$138K ﹤0.01% 2411
2019
Q1 		$19M Buy
19,102
+103
+0.5% +$95.7K 0.01% 2084
2018
Q4 		$16.5M Buy
18,999
+9,833
+107% +$9.13M 0.01% 2089
2018
Q3 		$9.47M Buy
9,166
+8,684
+1,802% +$8.49M ﹤0.01% 2462
2018
Q2 		$443K Sell
482
-397
-45% -$426K ﹤0.01% 3141
2018
Q1 		$857K Sell
879
-32
-4% -$29.2K ﹤0.01% 3024
2017
Q4 		$412K Hold
911
– – ﹤0.01% 3120
2017
Q3 		$377K Buy
911
+42
+5% +$15.8K ﹤0.01% 3140
2017
Q2 		$304K Buy
869
+25
+3% +$9.63K ﹤0.01% 3161
2017
Q1 		$434K Sell
844
-28
-3% -$11.6K ﹤0.01% 3111
2016
Q4 		$310K Buy
872
+235
+37% +$99.5K ﹤0.01% 3156
2016
Q3 		$340K Buy
+637
New +$346K ﹤0.01% 3121

Other funds holding ATRA

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Dimensional Fund Advisors's ATRA Position: Q1 2026 in Review

Dimensional Fund Advisors sold out of Atara Biotherapeutics (ATRA) in Q1 2026, closing a stake of 10,028 shares — an estimated $181K sold.

Dimensional Fund Advisors first reported a position in ATRA in Q3 2016 and held it in 30 quarters. The position peaked at $20.8M in Q2 2021. 33 funds tracked by Wall St. Rank hold ATRA as of Q1 2026.

  • Dimensional Fund Advisors reported no remaining Atara Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Dimensional Fund Advisors sold 10,028 Atara Biotherapeutics shares in Q1 2026, an estimated $181K.
  • Dimensional Fund Advisors first reported a position in Atara Biotherapeutics in Q3 2016 and held it in 30 quarters.
  • Dimensional Fund Advisors's Atara Biotherapeutics position peaked at $20.8M in Q2 2021.
  • 33 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2026.

Based on Dimensional Fund Advisors's 13F filing for Q1 2026, filed 7 May 2026.